HDAC7是急性红白血病潜在治疗靶点
研究建立Trp53缺失联合ERG过表达的小鼠急性红白血病模型,移植后两个月内100%发病,并证实该组合在人脐带血细胞中协同促进未成熟红系细胞生长;基于DepMap两两比较分析鉴定HDAC7为急性红白血病特异性易感基因,其通过非酶功能促进人和小鼠急性红白血病细胞体内外生长。
要点
- Trp53缺失小鼠骨髓细胞过表达ERG可在移植后两个月内以100%外显率发生急性红白血病。
- ERG过表达拮抗KLF1抑制红系成熟,TP53缺失促进红系祖细胞增殖。
- HDAC7通过非酶功能促进人和小鼠急性红白血病细胞体内外生长,为潜在治疗靶点。
核心结论
- TP53缺失与ERG过表达是急性红白血病发生的必要且充分条件,HDAC7是该病有前景的治疗靶点。
研究设计与样本
- 研究建立Trp53缺失联合ERG过表达的小鼠急性红白血病模型,并在人脐带血细胞中验证。
- 通过基于DepMap的两两比较分析鉴定急性红白血病特异性易感基因。
主要发现
- Trp53缺失小鼠骨髓细胞过表达ERG后移植,两个月内以100%外显率发生急性红白血病,而野生型骨髓细胞过表达ERG未发生。
- 建立的小鼠急性红白血病细胞表达Cas9,可在体外培养、在未照射受体小鼠体内诱导急性红白血病,并可用CRISPR/Cas9系统高效敲除基因。
- 在人脐带血细胞中证实ERG过表达与TP53失活协同促进未成熟红系细胞生长。
- 机制上ERG拮抗KLF1抑制红系成熟,TP53缺失促进红系祖细胞增殖。
- HDAC7通过非酶功能促进人和小鼠急性红白血病细胞体内外生长。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute erythroleukemia (AEL) is a rare subtype of acute myeloid leukemia with a poor prognosis. In this study, we established a novel murine AEL model with Trp53 depletion and ERG overexpression. ERG overexpression in Trp53-deficient mouse bone marrow cells, but not in wild-type bone marrow cells, leads to AEL development within two months after transplantation with 100% penetrance. The established mouse AEL cells expressing Cas9 can be cultured in vitro, induce AEL in vivo even in unirradiated recipient mice, and enable efficient gene ablation using the CRISPR/Cas9 system. We also confirmed the cooperation between ERG overexpression and TP53 inactivation in promoting the growth of immature erythroid cells in human cord blood cells. Mechanistically, ERG antagonizes KLF1 and inhibits erythroid maturation, whereas TP53 deficiency promotes proliferation of erythroid progenitors. Furthermore, we identified HDAC7 as a specific susceptibility in AEL by the DepMap-based two-group comparison analysis. HDAC7 promotes the growth of human and mouse AEL cells both in vitro and in vivo through its non-enzymatic functions. Our study provides experimental evidence that TP53 deficiency and ERG overexpression are necessary and sufficient for the development of AEL and highlights HDAC7 as a promising therapeutic target for this disease.
引用
- Zhang W, Yamamoto K, Chang YH, et al. HDAC7 is a potential therapeutic target in acute erythroid leukemia. Leukemia. 2024. PMID: 39277669. doi:10.1038/s41375-024-02394-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。